Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Injectafer Generic Name & Formulations
Legal Class
Rx
General Description
Elemental iron (as ferric carboxymaltose) 50mg/mL; soln for IV inj; preservative-free.
Pharmacological Class
Hematinic.
How Supplied
Single-dose vial (15mL)—1
Manufacturer
Generic Availability
NO
Injectafer Indications
Indications
Iron deficiency anemia (IDA) in patients ≥1yr of age who have intolerance or insufficient response to oral iron. In adults who have non-dialysis-dependent chronic kidney disease.
Injectafer Dosage and Administration
Adults and Children
<1yr: not established (IDA). Give by slow IV push (undiluted) at rate of approx. 100mg (2mL)/min; or by IV infusion (diluted) over 15mins. When giving via IV infusion, dilute to concentration not less than 2mg/mL of iron. ≥1yr (<50kg): 15mg/kg/dose in 2 doses separated by ≥7 days per course; (≥50kg): 750mg/dose in 2 doses separated by ≥7 days (total cumulative dose per course: 1500mg). For adults (≥50kg): alternatively can give 15mg/kg (up to max 1000mg) as a single-dose. May repeat treatment if IDA reoccurs.
Injectafer Contraindications
Not Applicable
Injectafer Boxed Warnings
Not Applicable
Injectafer Warnings/Precautions
Warnings/Precautions
Monitor for hypersensitivity reactions during and after administration for ≥30mins and until clinically stable. Have epinephrine inj immediately available. Possible risk for hypophosphatemia if history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, hyperparathyroidism, vitamin D deficiency, malnutrition. Monitor serum phosphate levels in at-risk patients who require a repeat course. Monitor for hypertension after each administration. Avoid extravasation. Neonates. Pregnancy (risk of fetal bradycardia esp. during 2nd & 3rd trimester). Nursing mothers.
Injectafer Pharmacokinetics
See Literature
Injectafer Interactions
Interactions
Possible risk for hypophosphatemia with concurrent or prior use of drugs that affect proximal renal tubular function. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.
Injectafer Adverse Reactions
Adverse Reactions
Nausea, hypertension, flushing, hypophosphatemia, dizziness; rare: hypersensitivity reactions.
Injectafer Clinical Trials
See Literature
Injectafer Note
Not Applicable
Injectafer Patient Counseling
See Literature
Images
